The stock of Vir Biotechnology Inc (VIR) has seen a 29.62% increase in the past week, with a 4.14% gain in the past month, and a 26.89% flourish in the past quarter. The volatility ratio for the week is 5.91%, and the volatility levels for the past 30 days are at 8.05% for VIR. The simple moving average for the last 20 days is 15.23% for VIR’s stock, with a simple moving average of 5.93% for the last 200 days.
Is It Worth Investing in Vir Biotechnology Inc (NASDAQ: VIR) Right Now?
The 36-month beta value for VIR is at 0.49. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 4 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for VIR is 87.31M, and currently, shorts hold a 6.31% of that float. The average trading volume for VIR on December 03, 2024 was 1.07M shares.
VIR) stock’s latest price update
Vir Biotechnology Inc (NASDAQ: VIR)’s stock price has soared by 18.33 in relation to previous closing price of 8.15. Nevertheless, the company has seen a gain of 29.62% in its stock price over the last five trading days. businesswire.com reported 2024-11-26 that SAN FRANCISCO–(BUSINESS WIRE)–Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will host a virtual investor event to discuss initial data from the dual-masked Phase 1 T-cell engagers VIR-5818 targeting a variety of HER2-expressing solid tumors and VIR-5500 targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC) along with updates on the PRO-XTEN™ platform on January 8, 2025, at 5:00 a.m. PT / 8:00 a.m. ET. A live webcast will be available on https://investors.vir.bio/.
Analysts’ Opinion of VIR
Many brokerage firms have already submitted their reports for VIR stocks, with JP Morgan repeating the rating for VIR by listing it as a “Neutral.” The predicted price for VIR in the upcoming period, according to JP Morgan is $9 based on the research report published on January 29, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see VIR reach a price target of $14, previously predicting the price at $23. The rating they have provided for VIR stocks is “Neutral” according to the report published on September 08th, 2023.
JP Morgan gave a rating of “Overweight” to VIR, setting the target price at $34 in the report published on March 06th of the previous year.
VIR Trading at 21.42% from the 50-Day Moving Average
After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.33% of loss for the given period.
Volatility was left at 8.05%, however, over the last 30 days, the volatility rate increased by 5.91%, as shares sank -0.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +23.03% upper at present.
During the last 5 trading sessions, VIR rose by +25.67%, which changed the moving average for the period of 200-days by -8.78% in comparison to the 20-day moving average, which settled at $8.35. In addition, Vir Biotechnology Inc saw -4.14% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VIR starting from VANINA ALEXANDRA HUARD DE VERN, who proposed sale 76 shares at the price of $8.22 back on Dec 02 ’24. After this action, VANINA ALEXANDRA HUARD DE VERN now owns shares of Vir Biotechnology Inc, valued at $625 using the latest closing price.
de Verneuil Vanina, the EVP and General Counsel of Vir Biotechnology Inc, sale 4,397 shares at $10.11 during a trade that took place back on Nov 06 ’24, which means that de Verneuil Vanina is holding 56,973 shares at $44,454 based on the most recent closing price.
Stock Fundamentals for VIR
Current profitability levels for the company are sitting at:
- -6.58 for the present operating margin
- 0.82 for the gross margin
The net margin for Vir Biotechnology Inc stands at -6.78. The total capital return value is set at -0.37. Equity return is now at value -36.58, with -30.10 for asset returns.
Currently, EBITDA for the company is -664.85 million with net debt to EBITDA at 0.26. When we switch over and look at the enterprise to sales, we see a ratio of 14.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.94.
Conclusion
In conclusion, Vir Biotechnology Inc (VIR) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
